New daily pill shows promise in early breast cancer trial
NCT ID NCT03850873
First seen May 04, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking certain proteins that help cancer cells multiply. The main goals were to find a safe dose and understand how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, 100039, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 45008, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 212028, China
-
The Fourth Hospital of Hebei Medical University and Hebei
Shijiazhuang, Hebei, 050011, China
Conditions
Explore the condition pages connected to this study.